Seven Fleet Capital Management LP Takes $1.17 Million Position in Vaxcyte, Inc. $PCVX

Seven Fleet Capital Management LP purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 25,365 shares of the company’s stock, valued at approximately $1,170,000. Vaxcyte comprises 0.9% of Seven Fleet Capital Management LP’s holdings, making the stock its 19th biggest holding.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares in the last quarter. Allworth Financial LP grew its stake in shares of Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Vaxcyte during the third quarter valued at approximately $45,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other news, CEO Grant Pickering sold 2,000 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total value of $105,000.00. Following the transaction, the chief executive officer owned 135,215 shares of the company’s stock, valued at $7,098,787.50. This represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the transaction, the chief operating officer owned 158,494 shares in the company, valued at $7,848,622.88. This represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 41,961 shares of company stock worth $2,233,490 over the last quarter. 3.30% of the stock is currently owned by insiders.

Vaxcyte Trading Up 1.5%

Shares of NASDAQ PCVX opened at $51.44 on Friday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The firm’s 50-day moving average is $53.56 and its 200-day moving average is $52.70. The firm has a market capitalization of $7.43 billion, a PE ratio of -7.48 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period last year, the company earned ($1.04) EPS. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PCVX. BTIG Research boosted their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Finally, Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.